Zacks Research Has Bullish Estimate for IRWD Q2 Earnings

Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD - Free Report) - Zacks Research raised their Q2 2025 earnings estimates for Ironwood Pharmaceuticals in a report released on Thursday, May 1st. Zacks Research analyst R. Department now expects that the biotechnology company will earn $0.03 per share for the quarter, up from their previous estimate of $0.01. The consensus estimate for Ironwood Pharmaceuticals' current full-year earnings is $0.10 per share. Zacks Research also issued estimates for Ironwood Pharmaceuticals' Q4 2025 earnings at $0.12 EPS, FY2025 earnings at $0.21 EPS, Q1 2026 earnings at $0.04 EPS, Q2 2026 earnings at $0.07 EPS, Q3 2026 earnings at $0.10 EPS, Q4 2026 earnings at $0.08 EPS, FY2026 earnings at $0.30 EPS, Q1 2027 earnings at $0.03 EPS and FY2027 earnings at $0.12 EPS.

Ironwood Pharmaceuticals (NASDAQ:IRWD - Get Free Report) last released its quarterly earnings data on Wednesday, May 7th. The biotechnology company reported ($0.14) earnings per share for the quarter, missing the consensus estimate of ($0.05) by ($0.09). The business had revenue of $41.14 million during the quarter, compared to analysts' expectations of $67.02 million. Ironwood Pharmaceuticals had a negative return on equity of 0.96% and a negative net margin of 0.65%.

A number of other research firms also recently issued reports on IRWD. Craig Hallum downgraded shares of Ironwood Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a research note on Wednesday, April 16th. Citizens Jmp lowered Ironwood Pharmaceuticals from an "outperform" rating to a "market perform" rating in a research report on Monday, April 14th. Leerink Partners decreased their price objective on Ironwood Pharmaceuticals from $3.00 to $1.00 and set a "market perform" rating for the company in a report on Monday, April 14th. Wells Fargo & Company reissued an "equal weight" rating and set a $1.00 price objective (down previously from $7.00) on shares of Ironwood Pharmaceuticals in a research report on Tuesday, April 15th. Finally, Jefferies Financial Group restated a "hold" rating and issued a $0.70 price objective (down previously from $8.00) on shares of Ironwood Pharmaceuticals in a report on Tuesday, April 15th. Seven analysts have rated the stock with a hold rating and two have given a buy rating to the company's stock. According to MarketBeat, Ironwood Pharmaceuticals has a consensus rating of "Hold" and an average target price of $4.78.

Ironwood Pharmaceuticals Price Performance

Ironwood Pharmaceuticals stock traded up $0.01 during mid-day trading on Monday, reaching $0.71. 494,792 shares of the company traded hands, compared to its average volume of 2,554,443. The firm's 50 day moving average price is $1.17 and its 200 day moving average price is $2.69. Ironwood Pharmaceuticals has a 52-week low of $0.59 and a 52-week high of $7.22. The firm has a market capitalization of $115.35 million, a price-to-earnings ratio of -23.76 and a beta of 0.37.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Virtu Financial LLC bought a new position in shares of Ironwood Pharmaceuticals during the 3rd quarter valued at $78,000. Hennion & Walsh Asset Management Inc. grew its stake in shares of Ironwood Pharmaceuticals by 9.9% during the 4th quarter. Hennion & Walsh Asset Management Inc. now owns 187,773 shares of the biotechnology company's stock valued at $832,000 after purchasing an additional 16,962 shares during the period. SG Americas Securities LLC purchased a new stake in shares of Ironwood Pharmaceuticals during the 4th quarter valued at about $53,000. Pacer Advisors Inc. lifted its stake in shares of Ironwood Pharmaceuticals by 4.0% in the 4th quarter. Pacer Advisors Inc. now owns 11,730,771 shares of the biotechnology company's stock worth $51,967,000 after purchasing an additional 450,949 shares during the period. Finally, EMC Capital Management boosted its holdings in shares of Ironwood Pharmaceuticals by 693.0% in the fourth quarter. EMC Capital Management now owns 23,893 shares of the biotechnology company's stock worth $106,000 after buying an additional 20,880 shares during the last quarter.

Insider Activity at Ironwood Pharmaceuticals

In other Ironwood Pharmaceuticals news, CEO Thomas A. Mccourt sold 139,064 shares of the business's stock in a transaction dated Monday, February 10th. The stock was sold at an average price of $1.76, for a total value of $244,752.64. Following the completion of the transaction, the chief executive officer now owns 1,160,634 shares of the company's stock, valued at approximately $2,042,715.84. The trade was a 10.70 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CMO Michael Shetzline sold 41,269 shares of the firm's stock in a transaction dated Monday, February 10th. The shares were sold at an average price of $1.76, for a total transaction of $72,633.44. Following the sale, the chief marketing officer now directly owns 554,007 shares in the company, valued at approximately $975,052.32. The trade was a 6.93 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 192,381 shares of company stock valued at $338,591 over the last 90 days. Corporate insiders own 12.90% of the company's stock.

Ironwood Pharmaceuticals Company Profile

Ironwood Pharmaceuticals, Inc, a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries.